Not provided
Not provided
Not provided
Not provided
no safety issues
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a phase II randomized, double-blind, placebo-controlled study where eligible subfertile male subjects (age 20 years).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MCS-5 | Active Comparator | Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks |
|
| Placebo | Placebo Comparator | Group 4: Placebo for 16 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MCS | Drug | MCS-5 Softgel 5 mg |
|
| Measure | Description | Time Frame |
|---|---|---|
| To compare changes in total motile sperm (TMS) between groups from baseline to 16 weeks after treatment | 16 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Taiwan University Hospital | Taipei | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided